Product Description
novel multi-kinase inhibitor; Notably, ON 123300's ability to target multiple kinase pathways that are overexpressed in cancer may allow for single-agent efficacy and better tolerability compared to existing treatment regimens. (Sourced from: https://investor.onconova.com/news-releases/news-release-details/onconova-therapeutics-announces-initial-dosing-first-patient-us)
Mechanisms of Action: CDK4 Inhibitor, CDK6 Inhibitor, ARK5 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Traws Pharma
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Onconova presented P0 Mantle-Cell Lymphoma results on 2023-12-11 for Narazaciclib
- Clinical Outcomes Reported - Onconova presented P0 Oncology Solid Tumor Unspecified results on 2023-12-08 for Narazaciclib
Highest Development Phases
Phase 2: Endometrial Cancer|Glioblastoma|Glioma
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05731934 |
HX301-I-01 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2024-01-12 |
12% |
2024-07-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06703255 |
Grade III and IV | P2 |
Recruiting |
Glioma |
2026-12-31 |
12% |
2025-01-16 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT05705505 |
NCT05705505 | P2 |
Recruiting |
Endometrial Cancer |
2026-01-01 |
12% |
2024-05-04 |
Primary Endpoints|Treatments |
CTR20200063 |
CTR20200063 | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20244225 |
CTR20244225 | P2 |
Recruiting |
Glioblastoma |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |